Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Resimmune (VG712)
i
Other names:
VG712, A-dmDT390-bisFv(UCHT1), UCHT-1, A-dmDT390-anti-CD3 immunotoxin, A-dmDT390-bisFv, LAX-699, LAX699, UCHT1, VG-712, LAX 699, UCHT 1, VG 712
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
AOP Orphan Pharma, Angimmune, Virogen Biotech
Drug class:
Elongation factor 2 inhibitor, CD3 inhibitor
Related drugs:
‹
tagraxofusp-erzs (5)
D2C7-IT (0)
EGFR bi-armed autologous activated T cells (0)
MGD007 (0)
muromonab-CD3 (0)
ertumaxomab (0)
SLAMF7 FPBMC (0)
anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells (0)
tagraxofusp-erzs (5)
D2C7-IT (0)
EGFR bi-armed autologous activated T cells (0)
MGD007 (0)
muromonab-CD3 (0)
ertumaxomab (0)
SLAMF7 FPBMC (0)
anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells (0)
›
Associations
News
Trials
Filter by
Latest
8d
CurbMF: A Study of VG712 in Patients With Mycosis Fungoides (clinicaltrials.gov)
P2, N=386, Not yet recruiting, Virogen Biotechnology Inc.
8 days ago
New P2 trial
|
Poteligeo (mogamulizumab-kpkc) • Resimmune (VG712)
Share via
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.